A Study to Investigate Ronde-cel Versus Investigator's Choice CD19 CAR T-Cell Therapy

计划入组 400 人 · 首次发布于 2025 年 9 月 23 日

Study of Rondecabtagene Autoleucel in Aggressive Large B-Cell Lymphoma

计划入组 270 人 · 首次发布于 2023 年 4 月 24 日

US Zamto-cel Autoimmune Diseases

计划入组 48 人 · 首次发布于 2024 年 11 月 27 日

ALLO-CEL

CEL-011

CEL-2000

CEL-SCI

United States

Adaptimmune Therapeutics

United Kingdom

Mines D`or Orbec Inc

United States

Lyell's Ronde-cel Shows 93% Response Rate in Large B-Cell Lymphoma with Enhanced Safety Profile

St. David's South Austin Medical Center Enrolls First Patient Globally in Phase III CAR T-Cell Trial for Aggressive Large B-Cell Lymphoma

CARVYKTI® Demonstrates Significant Benefit in High-Risk Multiple Myeloma After One Line of Therapy